Absolutely correct. There was nothing to lose by understating earnings. Overstate again and your credibility goes further into the crapper. Give some upward surprises with solid numbers and folks will think that a turn around is possible, even likely.
Fair question and you got a jerkoff answer. This is just my opinion but we bought a fair amount and did it on some careful analysis. First, the company is in a line of products that are not going away. There is absolute value here. The question is primarily around debt management and cash flow. The one thing I know for sure is that there is a lot smart money buying in, and there is smart money leaving. Different reasons for both sides. We are in $100K with an averaged price of $31. I am happy with that. I will throw up if it goes BK but I give that a 5% chance. I listened to an analyst in the VW stock and customer issues. I agree that it is largely a matter of trust. Until the trust has been established again, investors are going to be cautious. $60 by the end of the year is possible. I believe that management gave low guidance on the income. It was crucial for the boss to understate expectations. If you ever get a chance to talk with the CEO-CFO folks, the successful ones will tell you that it is important to underestimate your earnings.
And this my friend is why I am long and happy about it. I only go long. If it drops to 17-18, I don't care. It will go up, it will take a while and I am ok with that. The market may get an #$%$ whooping this year as it is. I am betting on a hold of 18 mos absent a buy out and I don't thin that likely.
Got in too high with first buy of 1K shares @ 50. Waited and now leveraged down to 29 with 4500 shares. Learned the hard way with PSTI. Huge upside there but I am way out of the $$ until it goes. I also believe that for all the sellers there are buyers and many have done a hard market analysis. The need for medications is not going away, only likely to increase.
Sentiment: Strong Buy
Good morning Stiff. I took the time to view the full 11 minute video. What is your take on it? He seems to raise some legitimate points. I'm DCA at 29 and feeling a little skittish. Thanks, CT
The one thing learned a while ago has to do with the value of time. The more that time passes the more likely that the data will get stale, that you will fall behind, that the space is open for others to move in. I would really like to know why the muscle trials have not gone forward.
Allo, you seem to be able to get your hands on data and facts fairly quickly. I saw on the Pluristem website that the trial in Japan for IC is/was approved to start. There was some initial protocol acceptance in early 2015. There was more information from earlier this year. Do we know if any trials have started in Japan? By started I mean are there any centers actually recruiting and dosing patients? Management indicated that they have enough money on hand to fund the clinical trials to 2017.
Even though after some years of testing with no negative results, we are still going to be looked at askance by investors. I recently did a search on clinical trials failures and found that there are a whole boatload of them out there. Take a look for yourselves. If you haven't or if you don't it is on you. We all want to make money. That is why we are in it at a very early stage. I can easily see a $15 price tag on this stock within 18 months, perhaps less. That is a 600% upside. For me having to learn patience in this field has been the result of feeling frustrated and then learning all that I could about the company, biotechs in general and some about the management. caltrials=calletemp. I am still a believer.
Cmon Allo. LIghten up a little. He is pro PSTI. There are some folks who are a little upset at how slow things have been going without management explanations.
Allo you great mystery person. How did you do it. I mean getting Google to name their new product after you? Sort of reminds me of the Great Oz but in reverse...........
Sentiment: Strong Buy
I think you may be confused about efficacy studies for the ARS cells. The reason for animal studies is to see if the drug works at all. For Radiation you simply can't get a group of test subjects and give them lethal doses of radiation to see if they survive (they likely would but some probably would not). The "animal rule" is specifically in place for use in situations where it is impossible or unethical to try the efficacy on humans. This is completely different that a safety study where the drug is administered to see how humans tolerate the drug. The hope is that if it works in animals and is safe for humans it will also work on humans. Pity the primates.
Just do a simple search on this. "Under its bond indentures, the Company has until June 11, 2016, 60 days from the receipt of the notice, to file its 10-K, which will cure the default in all respects." Limit your search to the past 24 hours. If you don't get the desired result include VRX.
Sentiment: Strong Buy
None of the Centerbridge or any other debt holders issues with default is worth discussing at the moment. Either VRX files the required statements or they don't. The overwhelming likelihood is that they will file on time and in line. What is going to matter will be what the documents show. What does merit discussing are the continuous analyst reports. NONE OF THEM point to anything other than continued business performance and price points substantially higher than where the stock is now.
Ahh numnuts. That is correct. Check out my other alias. Created calletemp for purposes you don't need to know about. Now about my post. How about some intelligent posts with a factual basis. My mental image of you is that you are sitting at your computer, in your underwear, in your mommy's basement.......... trying to be someone.